CG Oncology (CGON) said Friday it has sped up the timeline for the topline data readout of the phase 3 clinical trial of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer to H1 2026, nearly a year ahead of schedule because of early enrollment of 360 patients.
Chairman and Chief Executive Arthur Kuan said the company hopes to bring forward a potential indication for cretostimogene, an investigational immunotherapy, as a treatment for non-muscle bladder cancer.
Shares of the company were up over 6% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments